View Financial HealthPila Pharma 배당 및 자사주 매입배당 기준 점검 0/6Pila Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-55.3%자사주 매입 수익률총 주주 수익률-55.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jul 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.6m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (kr1.1m revenue, or US$116k). Market cap is less than US$10m (€4.84m market cap, or US$5.50m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr24m net loss in 3 years).공고 • Jul 24Pila Pharma AB (publ) to Report Fiscal Year 2026 Results on Mar 19, 2027Pila Pharma AB (publ) announced that they will report fiscal year 2026 results on Mar 19, 2027공고 • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.공고 • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026공고 • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.공고 • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.공고 • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026공고 • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026공고 • Jan 02+ 2 more updatesPila Pharma AB (publ) to Report Fiscal Year 2024 Results on Mar 27, 2025Pila Pharma AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Mar 27, 2025공고 • Dec 19Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic DiseasesPILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight.공고 • Nov 14PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study DesignPILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity.Reported Earnings • Aug 28First half 2024 earnings releasedFirst half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023).공고 • Apr 24Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024공고 • Apr 20+ 1 more updatePila Pharma AB (Publ) Announces Board and Management AppointmentsPila Pharma AB at the Annual General Meeting held on April 18, 2024 announced its founder and Director of the Board, Dorte X. Gram was elected new Chairman of the Board with immediate effect. The newly elected Board of Directors has subsequently appointed Dorte X. Gram as Chief Scientific Officer (CSO) of Pila Pharma AB. Further two new members have been elected to strengthen the Boards financial, strategic and market insight, thus recalibrating the objectives of Pila Pharma AB. Lasse Richter Petersen has been elected Director of the Board due to his extensive background and experience in the international pharmaceutical business including diabetes, and Julie Waras Brogren has been elected Director of the Board due to her extensive experience in developing strategies for advancing pharma assets from development to commercialisation and in finance and investor relations.Reported Earnings • Feb 29Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022)Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022).공고 • Dec 06Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,385,920 Price\Range: SEK 1.5 Transaction Features: Rights OfferingReported Earnings • Oct 28Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022).Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022).Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director of the Board Richard Busellato was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 27First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022)First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022).Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jul 02Pila Pharma AB (Publ) Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has BegunPila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months.Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Apr 26Pila Pharma AB Announces Certification of APIPila Pharma AB announced that the study material to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This production has now been completed as Almac has verified that the final product complies with the specifications and has issued a certificate of analysis. This in turn means that Pila Pharma's development of a new diabetes drug is going according to plan, and that the company can now proceed towards the planned longer preclinical studies that are necessary to be able to carry out a clinical phase 2b study.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 5KC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 5KC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Pila Pharma 배당 수익률 vs 시장5KC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (5KC)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (5KC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 5KC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 5KC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 5KC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 5KC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/04 16:48종가2026/08/03 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pila Pharma AB (publ)는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Filip EinarssonRedeye
New Risk • Jul 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.6m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (kr1.1m revenue, or US$116k). Market cap is less than US$10m (€4.84m market cap, or US$5.50m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr24m net loss in 3 years).
공고 • Jul 24Pila Pharma AB (publ) to Report Fiscal Year 2026 Results on Mar 19, 2027Pila Pharma AB (publ) announced that they will report fiscal year 2026 results on Mar 19, 2027
공고 • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.
공고 • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026
공고 • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.
공고 • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.
공고 • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
공고 • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026
공고 • Jan 02+ 2 more updatesPila Pharma AB (publ) to Report Fiscal Year 2024 Results on Mar 27, 2025Pila Pharma AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Mar 27, 2025
공고 • Dec 19Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic DiseasesPILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight.
공고 • Nov 14PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study DesignPILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity.
Reported Earnings • Aug 28First half 2024 earnings releasedFirst half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023).
공고 • Apr 24Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024
공고 • Apr 20+ 1 more updatePila Pharma AB (Publ) Announces Board and Management AppointmentsPila Pharma AB at the Annual General Meeting held on April 18, 2024 announced its founder and Director of the Board, Dorte X. Gram was elected new Chairman of the Board with immediate effect. The newly elected Board of Directors has subsequently appointed Dorte X. Gram as Chief Scientific Officer (CSO) of Pila Pharma AB. Further two new members have been elected to strengthen the Boards financial, strategic and market insight, thus recalibrating the objectives of Pila Pharma AB. Lasse Richter Petersen has been elected Director of the Board due to his extensive background and experience in the international pharmaceutical business including diabetes, and Julie Waras Brogren has been elected Director of the Board due to her extensive experience in developing strategies for advancing pharma assets from development to commercialisation and in finance and investor relations.
Reported Earnings • Feb 29Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022)Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022).
공고 • Dec 06Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,385,920 Price\Range: SEK 1.5 Transaction Features: Rights Offering
Reported Earnings • Oct 28Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022).
Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022).
Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director of the Board Richard Busellato was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 27First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022)First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022).
Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jul 02Pila Pharma AB (Publ) Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has BegunPila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months.
Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Apr 26Pila Pharma AB Announces Certification of APIPila Pharma AB announced that the study material to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This production has now been completed as Almac has verified that the final product complies with the specifications and has issued a certificate of analysis. This in turn means that Pila Pharma's development of a new diabetes drug is going according to plan, and that the company can now proceed towards the planned longer preclinical studies that are necessary to be able to carry out a clinical phase 2b study.